Trial Profile
An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- Acronyms SHINE
- Sponsors Biogen; Ionis Pharmaceuticals
- 29 Mar 2024 This study has been Completed in Germany, According to European Clinical Trials Database record.
- 06 Oct 2023 Status changed from active, no longer recruiting to completed.
- 06 Oct 2023 Status changed from active, no longer recruiting to completed.